A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell lymphoma

Stephanie D. Schniederjan, Shiyong Li, Debra F. Saxe, Mary J. Lechowicz, Kathryn L. Lee, Paul Terry, Karen P. Mann

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Rapid and accurate differential diagnosis between Burkitt lymphoma (BL) and CD10+ diffuse large B-cell lymphoma (DLBCL) is imperative because their treatment differs. Recent studies have characterized several antigens differentially expressed in these 2 types of lymphoma. Our goal was to determine whether use of these markers would aid in the differential diagnosis of BL vs CD10+ DLBCL by flow cytometric immunophenotyping (FCI). Twenty-three cases of CD10+ B-cell lymphomas with available cryopreserved samples were identified (13 BL and 10 CD10+ DLBCL). Multiparameter FCI was performed using the following antibodies: CD18, CD20, CD43, CD44, and CD54 and isotype controls. Expression of CD44 and CD54 was detected at a significantly lower level in BL compared with CD10+ DLBCL (P = .001 and P = .01, respectively). There was not a significant difference in expression of CD18 and CD43. Our data show that expression of CD44 and CD54 differs significantly between BL and CD10+ DLBCL.

Original languageEnglish (US)
Pages (from-to)718-726
Number of pages9
JournalAmerican Journal of Clinical Pathology
Volume133
Issue number5
DOIs
StatePublished - May 1 2010

Fingerprint

Burkitt Lymphoma
Lymphoma, Large B-Cell, Diffuse
Antibodies
Immunophenotyping
Differential Diagnosis
B-Cell Lymphoma
Lymphoma
Antigens

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine

Cite this

A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell lymphoma. / Schniederjan, Stephanie D.; Li, Shiyong; Saxe, Debra F.; Lechowicz, Mary J.; Lee, Kathryn L.; Terry, Paul; Mann, Karen P.

In: American Journal of Clinical Pathology, Vol. 133, No. 5, 01.05.2010, p. 718-726.

Research output: Contribution to journalArticle

Schniederjan, Stephanie D. ; Li, Shiyong ; Saxe, Debra F. ; Lechowicz, Mary J. ; Lee, Kathryn L. ; Terry, Paul ; Mann, Karen P. / A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell lymphoma. In: American Journal of Clinical Pathology. 2010 ; Vol. 133, No. 5. pp. 718-726.
@article{b5fbfdf3fade4deca22caf8d5fc44c79,
title = "A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell lymphoma",
abstract = "Rapid and accurate differential diagnosis between Burkitt lymphoma (BL) and CD10+ diffuse large B-cell lymphoma (DLBCL) is imperative because their treatment differs. Recent studies have characterized several antigens differentially expressed in these 2 types of lymphoma. Our goal was to determine whether use of these markers would aid in the differential diagnosis of BL vs CD10+ DLBCL by flow cytometric immunophenotyping (FCI). Twenty-three cases of CD10+ B-cell lymphomas with available cryopreserved samples were identified (13 BL and 10 CD10+ DLBCL). Multiparameter FCI was performed using the following antibodies: CD18, CD20, CD43, CD44, and CD54 and isotype controls. Expression of CD44 and CD54 was detected at a significantly lower level in BL compared with CD10+ DLBCL (P = .001 and P = .01, respectively). There was not a significant difference in expression of CD18 and CD43. Our data show that expression of CD44 and CD54 differs significantly between BL and CD10+ DLBCL.",
author = "Schniederjan, {Stephanie D.} and Shiyong Li and Saxe, {Debra F.} and Lechowicz, {Mary J.} and Lee, {Kathryn L.} and Paul Terry and Mann, {Karen P.}",
year = "2010",
month = "5",
day = "1",
doi = "10.1309/AJCP0XQDGKFR0HTW",
language = "English (US)",
volume = "133",
pages = "718--726",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "5",

}

TY - JOUR

T1 - A novel flow cytometric antibody panel for distinguishing Burkitt lymphoma from CD10+ diffuse large B-cell lymphoma

AU - Schniederjan, Stephanie D.

AU - Li, Shiyong

AU - Saxe, Debra F.

AU - Lechowicz, Mary J.

AU - Lee, Kathryn L.

AU - Terry, Paul

AU - Mann, Karen P.

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Rapid and accurate differential diagnosis between Burkitt lymphoma (BL) and CD10+ diffuse large B-cell lymphoma (DLBCL) is imperative because their treatment differs. Recent studies have characterized several antigens differentially expressed in these 2 types of lymphoma. Our goal was to determine whether use of these markers would aid in the differential diagnosis of BL vs CD10+ DLBCL by flow cytometric immunophenotyping (FCI). Twenty-three cases of CD10+ B-cell lymphomas with available cryopreserved samples were identified (13 BL and 10 CD10+ DLBCL). Multiparameter FCI was performed using the following antibodies: CD18, CD20, CD43, CD44, and CD54 and isotype controls. Expression of CD44 and CD54 was detected at a significantly lower level in BL compared with CD10+ DLBCL (P = .001 and P = .01, respectively). There was not a significant difference in expression of CD18 and CD43. Our data show that expression of CD44 and CD54 differs significantly between BL and CD10+ DLBCL.

AB - Rapid and accurate differential diagnosis between Burkitt lymphoma (BL) and CD10+ diffuse large B-cell lymphoma (DLBCL) is imperative because their treatment differs. Recent studies have characterized several antigens differentially expressed in these 2 types of lymphoma. Our goal was to determine whether use of these markers would aid in the differential diagnosis of BL vs CD10+ DLBCL by flow cytometric immunophenotyping (FCI). Twenty-three cases of CD10+ B-cell lymphomas with available cryopreserved samples were identified (13 BL and 10 CD10+ DLBCL). Multiparameter FCI was performed using the following antibodies: CD18, CD20, CD43, CD44, and CD54 and isotype controls. Expression of CD44 and CD54 was detected at a significantly lower level in BL compared with CD10+ DLBCL (P = .001 and P = .01, respectively). There was not a significant difference in expression of CD18 and CD43. Our data show that expression of CD44 and CD54 differs significantly between BL and CD10+ DLBCL.

UR - http://www.scopus.com/inward/record.url?scp=77951932197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951932197&partnerID=8YFLogxK

U2 - 10.1309/AJCP0XQDGKFR0HTW

DO - 10.1309/AJCP0XQDGKFR0HTW

M3 - Article

VL - 133

SP - 718

EP - 726

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 5

ER -